Clinical trials: Herpes Simplex, Genital
Human Immunodeficiency Virus
Problems With Immune Recovery in the Gut Tissue
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and…
- Trial name
- NCT01460433
- Testing
- Genital and rectal swabbing
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Herpes Zoster, Shingles
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Trial name
- NCT01132716
- Testing
- Valacyclovir Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Herpes Genitalis
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).
- Trial name
- HSV-2 (NCT02837575)
- Testing
- VCL-HB01, Phosphate-buffered saline
- Where
- 15 sites in United States
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- Vical
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in…
- Trial name
- NCT06385327
- Testing
- ABI-5366
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Herpes Genitalis, Herpes Zoster
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
The objective of this study is to evaluate the safety and tolerability of single rising doses of ASP2151 under fasted condition in healthy male subjects.
- Trial name
- NCT02852876
- Testing
- ASP2151
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe Ltd.
Genital Herpes
Knowledge of Young Adults About Genital Herpes
Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection.
- Trial name
- HerpesG (NCT05675228)
- Testing
- data collection
- Where
- France
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Université de Reims Champagne-Ardenne
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
HIV Infections
Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison
It is difficult to detect the intestinal protozoal infections among the HIV-infected persons or travelers diarrhea by using the traditional microscopy or staining methods.
- Trial name
- NCT00739258
- Where
- Taiwan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Genital Herpes
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
- Trial name
- NCT06033261
- Testing
- mRNA-1608, BEXSERO
- Where
- 23 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Recurrent Genital Herpes
UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals
A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection
- Trial name
- NCT04714060
- Testing
- UB-621
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Genital Herpes
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and…
- Trial name
- PK/GUD (NCT00808405)
- Testing
- acyclovir
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV, HIV Infections
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily…
- Trial name
- NCT00803543
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Genital Herpes Simplex Type 2
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).
- Trial name
- NCT02030301
- Testing
- VCL-HB01, VCL-HM01, PBS
- Where
- 7 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Vical
Genital Herpes
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
The primary objectives of the study are: To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 (HSV-2).
- Trial name
- HSV15 (NCT04222985)
- Testing
- HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in…
- Trial name
- NCT06698575
- Testing
- ABI-1179
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Herpes Zoster, Shingles
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Trial name
- NCT01132729
- Testing
- Valacyclovir Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Genital Herpes Simplex Type 2
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2…
- Trial name
- NCT05432583
- Testing
- BNT163
- Where
- 6 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline